Capped nascent RNA sequencing reveals novel therapy-responsive enhancers in prostate cancer

Kellie A. Cotter, Sagar R. Shah, Mauricio I. Paramo, Shaoke Lou, Yao Li, Philip Rubin, You Chen, Mark Gerstein, Mark A. Rubin, Haiyuan YubioRxiv 2022 · DOI

TL;DR

This paper introduces PRO-cap sequencing as a highly sensitive method to identify and track enhancer activity in prostate cancer cells. They discovered novel therapy-responsive enhancers that traditional methods missed, demonstrating PRO-cap's power to reveal precise biological changes and improve our understanding of cancer progression and treatment response.

What Problem Does This Paper Address?

Identifying and understanding the function of enhancers, crucial regulatory elements in the genome, has been a significant challenge. While methods like ChIP-seq and ATAC-seq can identify potential enhancers based on epigenetic marks, they often have a high false-positive rate and may miss subtle but biologically relevant changes in enhancer activity. Specifically, in the context of prostate cancer, understanding how enhancers respond to therapeutic interventions like enzalutamide (ENZ) is critical for developing more effective treatments. The authors aim to address this by developing a more sensitive method to detect dynamic changes in enhancer activity, particularly in response to drug treatment.

Methods

The core of this study is the application of Precision Run-On and Capped RNA sequencing (PRO-cap). This technique is designed to capture and sequence nascent RNA transcripts, specifically focusing on transcription start sites (TSSs) that generate enhancer RNAs (eRNAs). The process involves:

  1. Nuclear run-on: Cells are treated with biotin-labeled nucleotides to label newly synthesized RNA.
  2. Biotin enrichment: Nascent transcripts are captured using streptavidin beads.
  3. Cap selection and adapter ligation: A crucial step where only capped nascent transcripts are selected and ligated with adapters. This allows for precise identification of transcription initiation sites, including those of eRNAs.

This PRO-cap method is then used to assess changes in enhancer activity in LNCaP prostate cancer cells treated with enzalutamide (ENZ). The authors also employed CRISPR interference (CRISPRi) for in vivo functional validation of identified enhancers.

Datasets

The study primarily utilizes data from:

  • LNCaP prostate cancer cell line: This cell line was used for PRO-cap experiments and functional validations.
  • Publicly available ChIP-seq and ATAC-seq data: These datasets were used for comparison and validation of PRO-cap findings, including data from LNCaP cells treated with ENZ and other relevant datasets for prostate cancer.
  • Whole genome sequencing data: From 286 PCa patients (ICGC) to analyze non-coding somatic mutations within identified enhancers.
  • PCa risk variant data: From Conti et al., 2021 to investigate potential overlaps with identified enhancers.
  • Published RNA-seq data: From multiple sources to assess gene expression changes in response to ENZ.

No new benchmarks were introduced, but the study compares its findings against existing benchmarks derived from ChIP-seq and ATAC-seq.

Key Insights and Ideas

  • PRO-cap is a highly sensitive enhancer detection tool: It can identify enhancers that traditional epigenomic methods (ChIP-seq, ATAC-seq) miss, particularly those with subtle changes in activity.
  • eRNA transcription is a reliable marker for enhancer activity: Changes in eRNA TSSs directly reflect functional changes in enhancers.
  • Prostate cancer treatment reveals novel drug-responsive enhancers: A significant portion of ENZ-responsive enhancers were not identified by previous methods, suggesting new therapeutic targets or mechanisms of resistance.
  • PRO-cap can uncover previously unknown enhancer loci: These loci exhibit hallmarks of PCa-relevant transcription factor binding, even in primary and metastatic lesions.
  • Non-coding variants in enhancers can be prioritized: PRO-cap identified regions that can help focus the search for cancer-associated somatic and germline mutations in non-coding regions.

Key Results

  • Identification of 6,189 high-confidence candidate enhancers in LNCaP cells using PRO-cap.
  • 853 of these enhancers showed significant changes in activity in response to ENZ treatment.
  • 67% and 54% of drug-responsive enhancers did not show similar changes in ChIP-seq and ATAC-seq data, respectively.
  • 79% of regions with increased eRNA transcription showed no other biochemical alterations, highlighting PRO-cap's unique ability to detect subtle changes.
  • CRISPRi targeting of PRO-cap-specific enhancers impaired ENZ regulation of downstream genes, validating their functional significance. For example, targeting enhancer #3 significantly reduced KCNMA1 expression, and targeting enhancer #1 significantly reduced CACNG4 expression.
  • Analysis of 286 PCa whole genomes identified 137 SNVs in ENZ-regulated enhancers, with 20 being recurrent.

Limitations and Future Work

  • Limitations: While PRO-cap is highly sensitive, it is still a relatively new technique, and its application across diverse cell types and conditions may require further optimization. The study focused on a single cell line (LNCaP), and validation in primary patient samples for all findings would strengthen the conclusions.
  • Future Work: The authors suggest that PRO-cap can be broadly applied to study enhancer dynamics in various biological contexts, including development, disease progression, and response to different treatments. Further investigation into the specific mechanisms by which these novel enhancers regulate gene expression and contribute to cancer progression and drug resistance is warranted. The identification of non-coding variants within these enhancers also opens avenues for personalized medicine approaches.

Summary updated

Abstract

Abstract Mounting evidence suggests that enhancer RNA (eRNA) transcription start sites (TSSs) provide higher sensitivity and specificity for enhancer identification than histone modifications and chromatin accessibility. The extent to which changes in eRNA transcription correspond to changes in enhancer activity, however, remains unclear. Here, we used precision run-on and capped RNA sequencing (PRO-cap) to assess changes in enhancer activity in response to treatment with the androgen receptor signaling inhibitor, enzalutamide (ENZ). We identified 6,189 high-confidence candidate enhancers in the human prostate cancer cell line, LNCaP; 853 of which demonstrated significant changes in activity in response to drug treatment. Notably, we found that 67% and 54% of drug-responsive enhancers did not show similar changes in activity in previous studies that utilized ChIP-seq and ATAC-seq, respectively. Strikingly, 79% of regions with increased eRNA transcription showed no other biochemical alterations, implying that PRO-cap can capture a set of precise changes in enhancer activity that classical approaches lack the sensitivity to detect. We performed in vivo functional validations of candidate enhancers and found that CRISPRi targeting of PRO-cap-specific drug-responsive enhancers impaired ENZ regulation of downstream target genes, suggesting that changes in eRNA TSSs mark true biological changes in enhancer activity with high sensitivity. Our study highlights the utility of using PRO-cap as a complementary approach to canonical biochemical methods for detecting precise changes in enhancer activity and, in particular, for better understanding disease progression and responses to treatment.
BibTeX
@misc{cotter2022capped,
  author = {Kellie A. Cotter and Sagar R. Shah and Mauricio I. Paramo and Shaoke Lou and Yao Li and Philip Rubin and You Chen and Mark Gerstein and Mark A. Rubin and Haiyuan Yu},
  title = {{Capped nascent RNA sequencing reveals novel therapy-responsive enhancers in prostate cancer}},
  year = {2022},
  doi = {10.1101/2022.04.08.487666},
  howpublished = {bioRxiv},
}
Figure